Comparison
Oxytocin vs. Pasireotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
50-56-6
396091-73-9
Molecular weight
1007.19 g/mol
1047.21 g/mol
Half-life
0.05 h
no data
Sequence
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2no data
Mechanism of action
Oxytocin
Oxytocin is synthesised in the hypothalamus and released via the posterior pituitary. Peripherally it binds the oxytocin receptor, a G-protein-coupled receptor, and through the phospholipase-C cascade and calcium release triggers contraction of uterine smooth muscle and milk ejection — the pharmacological basis of the obstetric approval. Centrally, oxytocin acts as a neuromodulator and has been linked to social bonding, trust and modulation of stress and anxiety circuits. Its central effects in humans are mechanistically incompletely understood, particularly because it is unclear to what extent peripherally or intranasally administered oxytocin crosses the blood-brain barrier.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
1
of which in humans
4
1
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
0
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Oxytocin and Pasireotid?
- Oxytocin is classified as "Research other", while Pasireotid is classified as "Research other". Oxytocin: Oxytocin is an endogenous nonapeptide hormone of the posterior pituitary. In synthetic form (Pitocin, Syntocinon) it has been approved for decades to induce and augment labour and to control postpartum uterine bleeding. Strictly separate from this is intranasal use to influence social behaviour, trust, anxiety or autism symptoms: this use is unapproved, purely experimental, and yields inconsistent and often negative results in controlled trials. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Oxytocin or Pasireotid?
- The highest available evidence level is "Human RCT" for Oxytocin and "Human RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Oxytocin and Pasireotid in Germany and the United States?
- Germany: Oxytocin — Prescription, Pasireotid — Prescription. United States: Oxytocin — Prescription, Pasireotid — Prescription. These are factual summaries with source and review date on the individual pages.